Please wait

PRESENTED BY: Phase 1 Trial Results with PRAME - targeted T - cell Receptor (TCR) T - cell Therapies in Synovial Sarcoma Dejka M. Araujo 1 , Manik Chatterjee 2 , Diwakar Davar 3 , Leonel Fernando Hernandez - Aya 4 , Ran Reshef 5 , Dmitry Pankov 6 , Delfi Krishna 7 , Friedrich Vollmer 7 , Ana Maia 7 , Regina Mendrzyk 7 , Cedrik Michael Britten 7 , Martin Wermke 8 1 The University of Texas MD Anderson Cancer Center, Houston, TX; 2 University Hospital Wuerzburg, Wuerzburg, Germany; 3 Department of Malignant Hematology and Medical Oncology, Pittsburgh, PA; 4 University of Miami, Miami, FL; 5 Columbia University Irving Medical Center, New York, NY; 6 Immatics, Houston, TX; 7 Immatics Biotechnologies GmbH, Tübingen, Germany; 8 TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) and IMA203CD8 are distinct investigational one - time autologous TCR T - cell therapies targeting the cancer - associated antigen PRAME, a novel target for synovial sarcoma • PRAME - targeted TCR T - cell therapies demonstrate an expected and manageable tolerability profile and durable antitumor activity in patients with metastatic synovial sarcoma • The potentially transformative clinical activity of PRAME - targeted TCR T - cell therapy in metastatic synovial sarcoma supports further development HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor Dejka M. Araujo, M.D., A bstract #11516 Data cutoff Mar 30, 2026

PRESENTED BY: Two Distinct Systemic TCR T - cell Therapies Designed to Target the Intracellular Tumor Antigen PRAME Anzutresgene autoleucel and IMA203CD8 are distinct investigational therapies, and their use has not been proven to be safe or effective. These invest ig ational therapies have not been approved by the United States FDA or any other regulatory agency outside of the US. a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided expression threshold applied to RNAseq data (ap proximate values; values between 95 - 100% shown as 95%). NSCLC, non - small cell lung cancer; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. PRAME is expressed in >50 cancers % PRAME+ patients a Indication 95% Cutaneous Melanoma 95% Synovial Sarcoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 90% Mucosal Melanoma 90% Uveal Melanoma 85% Ovarian Carcinoma Subtypes 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Esophageal Carcinoma Subtype 45% Small Cell Lung Cancer 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Bladder Carcinoma 20% Hepatocellular Carcinoma Anzutresgene autoleucel (anzu - cel, IMA203) IMA203CD8 CD4/CD8 T cells expressing CD8 αβ Engineered PRAME - specific TCR Engineered PRAME - specific TCR CD8 αβ Th1 cytokines and cytotoxic effector molecules Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: Phase 1 Multicenter Trial of Anzu - cel or IMA203CD8 in PRAME+ Solid Tumors IMA203 - 101: NCT03686124; a PRAME testing no longer required for indications with high PRAME prevalence, including synovial sarcoma; b outpatient IL - 2 administration at investigator’s discretion. ECOG PS , Eastern Cooperative Oncology Group Performance Status; IL , interleukin; IU , international unit; HLA, human leukocyte antigen; PRAME, preferentially expressed in melanoma; RECIST, Response Evaluation Cr ite ria in Solid Tumors; SOC , Standard of Care; SUBQ , subcutaneous Key Objectives Patients enrolled to PRAME cell therapy: • Anzu - cel (IMA203): n=9 • IMA203CD8: n=12 PRAME Cell Therapy Manufacturing (~2 weeks) Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING / MANUFACTURING TREATMENT / OBSERVATION FOLLOW UP PRAME Testing Biopsy or archived tissue a PRAME Cell Therapy one - time infusion Data cutoff Mar 30, 2026 Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 Low Dose IL - 2 b 1M IU SUBQ up to 10 days Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: All Patients Had Metastatic Synovial Sarcoma Includes 1 patient treated with anzu - cel and post - PD with IMA203CD8; ECOG, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; SLD, sum of longest diameter(s); TCR , T - cell receptor; ULN, upper limit of normal. IMA203CD8 Anzu - cel (IMA203) n=12 n=9 46 (20, 66) 49 (20, 63) Age, median (range) 4 (33) 3 (33) Female , n (%) 2 (17) 2 (22) ECOG PS 1 , n (%) 4 (33) 5 (56) LDH ≥1 x ULN, n (%) 8.1 (1.2, 41.1) 10.9 (3.8, 14.8) Tumor burden Target lesion SLD [cm], median (range) 2 (1, 5) 2 (2, 4) Target lesions, n, median (range) 11 (92) 5 (56) Lung metastasis, n (%) 2 (17) 1 (11) Bone metastasis, n (%) Baseline Characteristics IMA203CD8 Anzu - cel (IMA203) n=12 n=9 9 (75) 12 (100) 5 (42) 5 (42) 1 (8) 7 (78) 9 (100) 5 (56) 4 (44) 3 (33) Prior treatment, n (%) Radiation Chemotherapy, n (%) Targeted therapies, n (%) Pazopanib TCR T - cell therapy, n (%) 2 (1, 5) 5 (42) 3 (1, 6) 5 (56) Prior lines of systemic treatment Median, (range) ≥3, n (%) Treatment Experience n=12 n=9 Dose 1.59 (0.89, 10.00) 0.63 (0.35, 9.36) Total TCR T cells [x10 9 ], median (range) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516 PF1 SH2

PRESENTED BY: Anzu - cel (IMA203): Tolerability in Synovial Sarcoma a From start of LD - chemotherapy b From anzu - cel (IMA203) infusion. CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity sy ndrome; LD, lymphodepletion; TEAE, treatment - emergent adverse event. • Most frequent TEAEs were anticipated cytopenias associated with LD • No late onset or prolonged (Day ≥90 a ) grade ≥3 events observed, except for leukopenia and/or neutropenia in 2 patients • AESIs were low - grade (1 - 2), occurred by Day 30 b , and were transient • CRS was low - grade (1 - 2), expected and manageable, and resolved within 2 weeks • No HLH • 1 case of ICANS grade 1; onset Day 5, resolved in 2 days Adverse events of special interest (AESI) Grade ≥ 3 Any Grade Preferred term, n (%) 8 (89) 9 (100) Neutropenia 8 (89) 8 (89) Leukopenia 5 (56) 7 (78) Anemia 7 (78) 7 (78) Lymphopenia 4 (44) 7 (78) Thrombocytopenia 0 6 (67) Fatigue 0 6 (67) Nausea 0 5 (56) Vomiting 0 4 (44) Constipation 0 4 (44) Diarrhea 0 4 (44) Rash 0 3 (33) Alkaline phosphatase elevation 0 3 (33) Creatinine elevation 0 3 (33) Hypocalcemia 0 3 (33) Hypokalemia 0 3 (33) Hyponatremia 0 3 (33) Hypophosphatemia 0 3 (33) Insomnia 0 3 (33) Proteinuria 0 3 (33) Pyrexia 0 3 (33) Sinus tachycardia 0 3 (33) Transaminase elevation N=9 6 (67) CRS, any grade, n (%) 3 (33) Grade 1 3 (33) Grade 2 0 HLH, any grade, n (%) 1 (11) ICANS, any grade, n (%) 1 (11) Grade 1 TEAEs in ≥25% of patients (N=9) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: Anzu - cel (IMA203) : BOR in Patients with Synovial Sarcoma (n=9) 'DWDFXW RII 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ 6SLGHU3ORW 6DUFRPD ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 3' %DVHOLQH 35 Clinical activity including durable responses observed at all dose levels M e dian dose: 0.63 x10 9 total TCR T cells Best overall response (RECIST 1.1) SD PR cPR Change in Sum of Longest Diameter of Target Lesions from Baseline (%) ,QGLFDWLRQ 7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH :DWHUIDOO3ORW 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ 'DWDFXW RII 25 0 - 25 - 50 - 75 - 100 Baseline Change in Sum of Longest Diameter of Target Lesions from Baseline (%) a One patient with non - evaluable post - BL scan non included in assessment of tumor reduction and not depicted in plot but assessed for ORR calculation . ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfi rmed PR/CR were excluded. BL , baseline; (c)ORR, (confirmed) objective response rate; (c)PR , (confirmed) partial response; DCR, disease control rate; mDOR , median duration of response; mFU , median follow - up; NR, not reached; PD , progressive disease; SD , stable disease; TCR, T - cell receptor . Baseline PD PR Data cutoff Mar 30, 2026 Tumor reduction: 88% (7/8) 56% (5/9) ORR a 33% (3/9) cORR b 89% (8/9) DCR (at week 6) 10.5 (4.4, 23) NR mDOR (range), months mFU DL2 DL3 DL5 DL2 DL2 DL2 DL5 DL5 Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: IMA203CD8: Tolerability in Synovial Sarcoma a Testicular/scrotal disorders includes grouped terms; b Grade 3 CRS with transient Grade 3 hepatotoxicity improved to Grade 2 within 10 days; CRS resolved completely without need fo r v asopressors/ventilator support; c Further modification of the inclusion/exclusion criteria and IL - 2 scheme allowed continuation of dose escalation from DL4c up to present DL7; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; LD, lymphodepletion; MTD, maximum tolerated dose; TEAE, treatment - emergent adverse event. • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Infrequent long - term (Day ≥ 90) grade ≥3 TEAEs included cytopenias (n=6) and/or hypertension (n=2) • AESIs were low - grade (1 - 2), occurred early, and were transient • CRS was mostly low - grade (1 - 2), expected and manageable • No HLH or ICANS • 1 DLT b at DL4b (MTD not reached c ) Adverse events of special interest (AESI) Grade ≥ 3 Any Grade Preferred term, n (%) 12 (100) 12 (100) Neutropenia 6 (50) 11 (92) Anemia 4 (33) 11 (92) Thrombocytopenia 1 (8) 11 (92) Transaminase elevation 9 (75) 9 (75) Lymphopenia 0 8 (67) Nausea 0 6 (50) Fatigue 0 5 (42) Rash 1 (8) 4 (33) Creatinine elevation 0 4 (33) Constipation 0 4 (33) Headache 0 4 (33) Hyponatremia 1 (8) 4 (33) Hypophosphatemia 0 4 (33) Pyrexia 0 4 (33) Testicular/scrotal disorders a 0 3 (25) Back pain 0 3 (25) Dyspnoea 2 (17) 3 (25) Hypertension 0 3 (25) Insomnia 0 3 (25) Edema peripheral N=12 12 (100) CRS, any grade, n (%) 5 (42) Grade 1 5 (42) Grade 2 2 (17) Grade 3 0 HLH, any grade, n (%) 0 ICANS, any grade, n (%) TEAEs in ≥25% of patients (N=12) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: 'DWDFXW RII 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 6SLGHU3ORW 6DUFRPD ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 3' 3' %DVHOLQH %DVHOLQH 35 35 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 2QJRLQJ IMA203CD8: BOR in Patients with Synovial Sarcoma (n=12) a ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; cORR : according to RECIST 1.1 for patients with ≥2 post - BL scans, PD or death at any prior timepoint; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR were excluded. BL , baseline; BOR , best overall response; (c)CR , (confirmed) complete response; (c)ORR, (confirmed) objective response rate; (c)PR , (confirmed) partial response; DCR, disease control rate; mDOR , median duration of response; mFU , median follow - up; NR, not reached; PD , progressive disease; SD , stable disease; TCR, T - cell receptor. Clinical activity including durable responses observed at all dose levels Median dose: 1.59 x10 9 total TCR T cells Best overall response (RECIST 1.1) PD SD PR cPR CR cCR Ongoing ,QGLFDWLRQ %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %DVHOLQH 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 2QJRLQJ :DWHUIDOO3ORW 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 'DWDFXW RII 25 0 - 25 - 50 - 75 - 100 Change in Sum of Longest Diameter of Target Lesions from Baseline (%) 15 - 1 - 18 - 26 - 41 - 42 - 50 - 61 - 66 - 73 - 77 - 100 BL Data cutoff Mar 30, 2026 Tumor reduction: 92% (11/12) DL4a DL3 DL4a DL4b DL7 DL3 DL4a DL4a DL4a DL4a DL4a DL4b Dejka M. Araujo, M.D., A bstract #11516 67% (8/12) ORR a 64% (7/11) cORR b 100% (12/12) DCR (at week 6) 14.8 (3.7, 31.8+) 31.0 mDOR (range), months mFU

PRESENTED BY: Patient Case: Long - Term Disease Control of >4 Years After Prior TCR T - cell Therapies a At time of IMA203CD8 infusion, right pleura metastasis not selected as a target lesion; subsequent PET - CT on April 2025 demonst rated no evidence of FDG - avid malignancy BL , baseline; BOR , best overall response; CR , complete response; cPR , confirmed partial response; DL , dose level; PD , progressive disease; PFS , progression - free survival; SD , stable disease; TKI , Tyrosine Kinase Inhibitor. Soft tissue sarcoma S ubtype : synovial sarcoma BOR: CR Chemotherapy 2011 - 2012: BOR: SD TKI (Pazopanib) 2018: BOR: SD MAGE - A4 - directed TCR T - cell therapy 2019: Initial Diagnosis Sep 2011 Prior Systemic Treatments Oct 2011 – Sep 2019 Anzu - cel (IMA203) Apr 2021 IMA203CD8 Oct 2023 Analysis of single lesions over time Status at the time of PD with anzu - cel (IMA203) Target lesion site PD Right pulmonary hilum metastasis New lesion Right infrahilar lymph node (lymphadenopathy) No evidence of disease Right pleura metastasis Suspected fibrosis - touch preps were acellular; not selected as target lesion for IMA203CD8 a Right pleura metastasis a 0 R Q W K V I U R P 7 & H O O , Q I X V L R Q , 0 $ , 0 $ & ' , Q I X V L R Q 5 L J K W 3 X O P R Q D U \ K L O X P P D V V 5 L J K W , Q I U D K L O D U O \ P S K Q R G H O \ P S K D G H Q R S D W K \ 1 H Z / H V L R Q , 0 $ & ' % D V H O L Q H 6 F D Q * ( 1 * ( 1 6 \ Q R Y L D O ௐ 6 D U F R P D $ Q D O \ V L V R I V L Q J O H O H V L R Q R Y H U W L P H ! \ H D U V 5 L J K W S O H X U D P H W D V W D V L V 5 L J K W S O H X U D P H W D V W D V L V / H V L R Q V W D W X V D W W K H W L P H R I 3 ' * ( 1 3 ' 1 H Z O H V L R Q 1 R H Y L G H Q F H R I G L V H D V H 6 X V S H F W H G I L E U R V L V W R X F K S U H S V Z H U H D F H O O X O D U 3 ' F 3 ' 3 5 % / Anzu - cel Apr 2021 IMA203CD8 Oct 2023 1.8 x 10 9 total TCR T cells Dose: 6.1 cm BL tumor burden: 2 No of lesions: ongoing cPR ( - 48%) BOR: ongoing at 29.4 months PFS: 0.4 x 10 9 total TCR T cells Dose: 8.4 cm BL tumor burden: 3 No of lesions: cPR ( - 46%) BOR: 24.4 months PFS: Data cutoff Mar 30, 2026 Male, 49 y/o at first trial enrollment Dejka M. Araujo, M.D., A bstract #11516 cPD IMA203CD8 BL scan Last anzu - cel scan

PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) and IMA203CD8 are distinct investigational one - time autologous TCR T - cell therapies targeting the cancer - associated antigen PRAME, a novel target for synovial sarcoma • PRAME - targeted TCR T - cell therapies demonstrate an expected and manageable tolerability profile and durable antitumor activity in patients with metastatic synovial sarcoma • The potentially transformative clinical activity of PRAME - targeted TCR T - cell therapy in metastatic synovial sarcoma supports further development HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. Dejka M. Araujo, M.D., A bstract #11516 Data cutoff Mar 30, 2026

PRESENTED BY: Thank you — Trial Participants & Caregivers University Hospital Dresden University Hospital Würzburg University Hospital Hamburg IMA203 - 101 Phase 1 Trial ( patients with synovial sarcoma) Sponsor: Immatics University of Pittsburgh Medical Center UT MD Anderson United States University of Miami Health System Columbia University Medical Center Germany Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: Appendix Dejka M. Araujo, M.D., A bstract #11516

PRESENTED BY: Anzu - cel Phase 1 Study Design Data cutoff Mar 30, 2026 Total TCR T cells calculated from defined number of TCR T cells/m2 body surface area (BSA) per dose level x 1.8 m2 BSA (BSA o f a verage patient). BSA, body surface area; DL, dose level; DLT, dose - limiting toxicity; TCR, T - cell receptor. Total n=9 patients with synovial sarcoma DL1 (n=0) ~0.07 - 0.11 x 10 9 total TCR T cells DL2 (n=4) ~0.22 – 0.32 x 10 9 total TCR T cells DL3 (n=2) ~0.36 – 0.86 x 10 9 total TCR T cells DL4 (n=0) ~0.36 - 2.16 x 10 9 total TCR T cells DL5 (n=3) ~2.16 – 8.46 x 10 9 total TCR T cells Phase 1b Dose Expansion at RP2D (1 - 10 billion total TCR T cells) Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026

PRESENTED BY: Patients with Synovial Sarcoma Treated with Anzu - cel (IMA203) in Phase 1 a presented patient case; BOR , best overall response; DL , dose level; (c)PR , (confirmed) partial response; SD , stable disease; PD , progressive disease; PFS , progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Target and non - target progression Unconfirmed response until 2.8 months PFS - 75 PR DL5 3.94 Chemotherapy 1 Synovial Sarcoma Target progression and new lesions Response until 11.9 months PFS - 69 cPR DL5 6.01 TNF α + chemotherapy (melphalan) Chemotherapy 2 Synovial Sarcoma Target progression Response until 5.8 months PFS - 61 cPR DL2 0.39 Chemotherapy Chemotherapy 2 Synovial Sarcoma Target progression Response until 24.4 months PFS - 46 cPR DL2 0.41 Chemotherapy Pazopanib MAGEA4 TCR T - cell therapy 3 Synovial Sarcoma Target and non - target progression Unconfirmed response until 2.5 months PFS - 40 PR DL2 0.35 Chemotherapy Chemotherapy 2 Synovial Sarcoma Clinical PD Disease stabilization until 1.4 months PFS - 26 SD DL5 9.36 Chemotherapy Pazopanib Exp. therapy (NY - ESO - 1 TCR T cells) Pazopanib Exp. therapy (CFT8634) 5 Synovial Sarcoma Clinical PD Disease stabilization until 2.8 months PFS - 2 SD DL3 0.81 Chemotherapy Chemotherapy Chemotherapy Chemotherapy P azopanib MAGEA4 TCR T - cell therapy 6 Synovial Sarcoma a Target progression Disease stabilization until 2.5 months PFS 5 SD DL2 0.37 Chemotherapy Pazopanib Chemotherapy 3 Synovial Sarcoma Non - target progression Progressive disease at 1.4 months PFS n/a PD DL3 0.63 Chemotherapy Chemotherapy Chemotherapy Chemotherapy Pazopanib + chemotherapy 5 Synovial Sarcoma Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026

PRESENTED BY: Phase 1a Dose Escalation Study Design 1 Based on initial safety data observed with anzu - cel (IMA 203 ), dose escalation for IMA 203 CD 8 was initiated at DL 3 ; 2 DL 4 a cleared in Dec 2023 ; 3 DLTs at DL 4 b triggered modifications of the eligibility criteria, adapted patient population is treated with DL 4 c . Each dose level ≥ DL 4 c is evaluated “ IL - 2 : start without IL - 2 ; if considered tolerable, either add IL - 2 at the same dose, or escalate to the next dose without IL - 2 ; total TCR T cells calculated from defined number of TCR T cells/m 2 BSA per dose level x 1 . 8 m 2 BSA (BSA of average patient) . BSA, body surface area ; DL, dose level ; DLT, dose - limiting toxicity ; IL, interleukin ; TCR, T - cell receptor . DL3 1 (n=2) ~0.36 - 0.86 x 10 9 total TCR T cells DL4a 2 (n=7) ~0.87 - 1.44 x 10 9 total TCR T cells DL4b 3 (n=2) ~1.45 - 2.16 x 10 9 total TCR T cells DL4c (n=0) ~1.45 - 2.16 x 10 9 total TCR T cells DL5 (n=0) ~2.17 - 3.6 x 10 9 total TCR T cells DL6 (n= 0 ) ~3.6 - 7.2 x 10 9 total TCR T cells DL7 (n=1) ~ 7.2 - 10 x 10 9 total TCR T cells Median dose of 1.59 billion total IMA203CD8 TCR T cells Total n=12 patients with synovial sarcoma ц Low Dose IL - 2 Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026 PF1

PRESENTED BY: Patients with Synovial Sarcoma Treated with IMA203CD8 in Phase 1 BOR , best overall response; DL , dose level; cCR , confirmed complete response; (c)PR , (confirmed) partial response; SD , stable disease. PFS , progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 32.4 months PFS - 100 cCR 4b 2.05 Chemotherapy 1 Synovial Sarcoma Target progression Response until 16.1 months PFS - 77 cPR 4a 1.15 Chemotherapy 1 Synovial Sarcoma Ongoing response at 34.7 months PFS - 73 cPR 4a 1.56 Chemotherapy Chemotherapy 2 Synovial Sarcoma Target and non - target progression and news lesions Response until 6.1 months PFS - 66 cPR 4a 1.61 Chemotherapy Pazopanib Chemotherapy 3 Synovial Sarcoma Ongoing response at 29.4 months PFS - 61 cPR 4a 1.81 Chemotherapy Pazopanib MAGEA4 TCR T - cell therapy 3 Synovial Sarcoma Target and non - target progression Response until 5.7 months PFS - 50 cPR 4a 1.53 Chemotherapy 1 Synovial Sarcoma Target and non - target progression and new lesions Response until 4.9 months PFS - 42 cPR 3 1.00 Pazopanib + chemotherapy Pazopanib 2 Synovial Sarcoma Ongoing response at 6.7 months PFS (confirmatory scan results pending) - 41 PR 7 10.00 Chemotherapy 1 Synovial Sarcoma Target progression and new lesions Disease stabilization until 5.5. months PFS - 26 SD 4b 1.49 Chemotherapy Pazopanib Pazopanib 3 Synovial Sarcoma Target progression Disease stabilization until 2.8 months PFS - 18 SD 4a 1.75 Chemotherapy 1 Synovial Sarcoma Non - target progression and new lesions Disease stabilization until 2.8 months PFS - 1 SD 3 0.89 Chemotherapy Chemotherapy Chemotherapy Chemotherapy Chemotherapy 5 Synovial Sarcoma Clinical PD Disease stabilization until 2.9 months PFS 15 SD 4a 1.68 Chemotherapy Chemotherapy Chemotherapy Pazopanib Chemotherapy 5 Synovial Sarcoma Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026